US mRNA company Moderna (Nasdaq: MRNA) announced better-than-expected financial results and a $3 billion share buyback on Thursday.
The company’s fourth-quarter revenues reached $7.21 billion, which was more than 10 times higher than the same period in 2020, due to the launch and success of Moderna’s Spikevax vaccine for COVID-19.
"In 2021, we delivered 807 million doses"This figure also exceeded the FactSet consensus estimate of $6.8 billion. The same was true of Moderna’s diluted earnings of $11.29 per share, where analysts had expected $9.96 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze